cagrilintide vs cagrisema

cagrilintide (B-tier) vs cagrisema (B-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

cagrilintide · tier B

novo's long-acting amylin analog. 11.8% standalone weight loss in the phase-3 REDEFINE-1 trial (10.8% earlier in phase 2). the filed product is the cagrisema combo, not the monotherapy.

a long-acting amylin analog from novo. the standalone hit 11.8% weight loss in the phase-3 REDEFINE-1 trial (10.8% in phase 2 before that). the program novo actually filed with the FDA is the cagrisema combo, not cagrilintide alone.

10.8% Lau 2021 phase 2 · half-life ~7 days (once-weekly dosing) · weight loss

cagrisema · tier B

semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.

semaglutide + cagrilintide. the first fixed-dose GLP-1 + amylin combo. NDA filed December 2025, expected FDA decision late 2026.

22.7% REDEFINE-1 phase 3 · half-life ~168 hours (once-weekly dosing, both components) · weight loss

at a glance

• cagrilintide: tier B · 10.8% Lau 2021 phase 2
• cagrisema: tier B · 22.7% REDEFINE-1 phase 3

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.